Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
NEODECADRON is a fixed-dose ophthalmic combination of dexamethasone sodium phosphate (corticosteroid) and neomycin sulfate (aminoglycoside antibiotic) formulated as a topical eye drop solution. It treats bacterial infections and inflammatory conditions of the eye by reducing inflammation and suppressing bacterial growth. The product has been in use since 1969 and represents a legacy anti-infective/anti-inflammatory therapy for ocular indications.
As a legacy ophthalmic product approaching loss of exclusivity, the brand team is likely small and focused on maintaining market position against generic and newer alternatives in a contracting franchise.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NEODECADRON offers limited growth trajectory; the product is in defensive mode as it approaches loss of exclusivity. Career development is best suited for professionals focused on legacy product management, cost-containment strategy, and market access rather than innovation or launch leadership.
Worked on NEODECADRON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo